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Clinical background
HIV-infected patients are at increased risk to develop
Hodgkin lymphoma (HL). We examined the incidence
and risk factors for HL, the evolution of CD4 cell counts
before HL diagnosis and prognosis of patients with HIV-
related HL and in the era of combined antiretroviral
therapy (cART) in the Collaboration of Observational
HIV Epidemiological Research Europe (COHERE).
Patients and methods
40,168 adult HIV-1 infected patients who started cART
i no n eo f1 6p r o s p e c t i v ec o h o r ts t u d i e si nE u r o p ew e r e
included. Incidence rates per 100,000 person-years,
Kaplan-Meier estimates of cumulative incidence and
survival, and adjusted hazard ratios from Weibull
random-effects models, with 95% confidence intervals
(CIs), were calculated. CD4 counts over time were com-
pared between patients who were free of AIDS, on
cART and developed HL (cases), and control patients.
Cases and controls were matched 1:5 for cohort, age,
sex, risk group, CD4 cell count at start of cART, and
HIV-1 RNA at reference date, defined as HL diagnosis
(cases), or at identical length of followup since start of
cART (controls). We used multilevel linear regression to
model changes in CD4 cell counts after start of cART
and during the year before reference date and tested for
differences between slopes in cases and controls. The
analysis was repeated for patients with non-Hodgkin
lymphoma (NHL).
Results
During 159,133 person-years of followup, 78 patients
were diagnosed with HL. The crude incidence rate of
HL was 50.4 per 100,000 person-years for patients who
developed HL before starting cART (17 cases) and 48.7
per 100,000 person-years in patients who were already
on cART (61 cases). Age, gender, CDC clinical stage,
C D 4c e l lc o u n t ,a n dH I V - 1R N Av i r a ll o a da tb a s e l i n e
(start of observation) were not significantly associated
with the risk of HL. During a median followup of
18 months (IQR 4.8-34.8 months) 12 of 78 patients with
HL died. Survival was 88% (95% CI 77-94) at 1 year and
81% (95% CI 68-89) at 2 years. A total of 18 HL patients
were matched to 79 controls. At HL diagnosis, 16 of
18 cases (89%) had undetectable viral loads
(<500 copies/ml). The evolution of CD4 cell counts
before reference date differed: in HL patients the CD4
cell count increased after start of cART (+126 cells per
year) but declined during the year before the HL diag-
n o s i s( - 9 9c e l l sp e ry e a r ) .I nc o n t r o l st h eC D 4c e l l
counts increased throughout (+57 cells per year). Slopes
differed significantly during the year before the HL diag-
nosis (p=0.003), but not after start of cART (p=0.944);
s e eF i g u r e1 .I nN H Lp a t i e n t s ,t h eC D 4c e l lc o u n t
increased after start of cART (+131 cells per year) and
remained stable during the year before the NHL diagno-
sis (-16 cells per year). In controls CD4 cell counts
increased throughout (+ 38 cells per year).
Conclusions
HL incidence rates were similar in cART treated and
untreated patients. CD4 cells declined before HL
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load. In contrast, in NHL patients CD4 cell counts did
not sharply decrease in the year before NHL diagnosis.
Patients on successful cART who experience a sudden
decline of CD4 counts should be investigated for HL.
Acknowledgements
This article has been published as part of Infectious Agents and Cancer
Volume 5 Supplement 1, 2010: Proceedings of the 12
th International
Conference on Malignancies in AIDS and Other Acquired
Immunodeficiencies (ICMAOI). The full contents of the supplement are
available online at http://www.biomedcentral.com/1750-9378/5?issue=S1.
Published: 11 October 2010
doi:10.1186/1750-9378-5-S1-A34
Cite this article as: Egger and : HIV-related Hodgkin lymphoma in the
era of combination antiretroviral therapy: incidence, outcome, and
evolution of CD4+ T cell lymphocytes. Infectious Agents and Cancer 2010
5(Suppl 1):A34.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Figure 1 Evolution of CD4 cells in Hodgkin lymphoma cases and matched controls.
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